Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study |
Sayed, Rana
(Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University)
Saad, Amr S (Department of Clinical Oncology, Faculty of Medicine, Ain Shams University) El Wakeel, Lamia (Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University) Elkholy, Engi (Department of Clinical Oncology, Faculty of Medicine, Ain Shams University) Badary, Osama (Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University) |
1 | Wang SY, Chuang CS, Muo CH, et al (2013). Metformin and the incidence of cancer in patients with diabetes: a nested case-control study. Diabetes Care, 36, 155-6. |
2 | Witters LA (2001). The blooming of the French lilac. J Clin Invest, 108, 1105-7. DOI ScienceOn |
3 | Xiao YY, Zhan P, Yuan DM, et al (2013). Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials. Clin Oncol (R Coll Radiol), 25, 7-15. DOI |
4 | Yin M, Zhou J, Gorak EJ, et al (2013). Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncol, 18, 1248-55. DOI |
5 | Zhang ZJ, Li S (2014). The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab, [Epub ahead of print]. |
6 | Aljada A, Mousa SA (2012). Metformin and neoplasia: implications and indications. Pharmacol Ther, 133, 108-15. DOI |
7 | Ashinuma H, Takiguchi Y, Kitazono S, et al (2012). Antiproliferative action of metformin in human lung cancer cell lines. Oncol Rep, 28, 8-14. |
8 | Bolen S, Feldman L, Vassy J, et al (2007). Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med, 147, 386-99. DOI |
9 | Bost F, Sahra IB, Le Marchand-Brustel Y, et al (2012). Metformin and cancer therapy. Curr Opin Oncol, 24, 103-8. DOI |
10 | Bradford SA, Khan A (2013). Individualizing chemotherapy using the anti-diabetic drug, metformin, as an "adjuvant": an exploratory study. J Cancer Sci Ther, 5, 6. |
11 | Ceresoli GL, Cappuzzo F, Gregorc V, et al (2004). Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol, 15, 1042-7. DOI ScienceOn |
12 | Chakraborty A, Chowdhury S, Bhattacharyya M (2011). Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract, 93, 56-62. DOI |
13 | Han D, Li SJ, Zhu YT, et al (2013). LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer. Asian Pac J Cancer Prev, 14, 4033-9. DOI |
14 | Di Maio M, Bria E, Rossi A, et al (2008). Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter? Ann Oncol, 19, 402-3. DOI |
15 | Evans JM, Donnelly LA, Emslie-Smith AM, et al (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5. DOI |
16 | Forbes S, Clements J, Dawson E, et al (2006). COSMIC 2005. Br J Cancer, 94, 318-22. DOI ScienceOn |
17 | Janjetovic K, Vucicevic L, Misirkic M, et al (2011). Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol, 651, 41-50. DOI |
18 | Jiralerspong S, Palla SL, Giordano SH, et al (2009). Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol, 27, 3297-302. DOI |
19 | Klastersky J, Awada A (2012). Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol, 81, 49-57. |
20 | Ma Y, Guo FC, Wang W, et al (2013). Kras gene mutation as a predictor of cancer cell responsiveness to metformin. Mol Med Rep, 8, 763-8. |
21 | Mazzone PJ, Rai H, Beukemann M, et al (2012). The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer, 12, 410. DOI |
22 | Memmott RM, Mercado JR, Maier CR, et al (2010). Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila), 3, 1066-76. DOI |
23 | Okamoto T, Maruyama R, Shoji F, et al (2005). Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer, 47, 85-91. DOI ScienceOn |
24 | Micic D, Cvijovic G, Trajkovic V, et al (2011). Metformin: its emerging role in oncology. Hormones (Athens), 10, 5-15. DOI |
25 | Na, II, Choe du H, Kim CH, et al (2010). Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer. Lung Cancer, 68, 295-8. DOI |
26 | Nie SP, Chen H, Zhuang MQ, et al (2014). Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and metaanalysis. Asian Pac J Cancer Prev, 15, 6863-9. DOI |
27 | Paesmans M, Sculier JP, Libert P, et al (1995). Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European lung cancer working party. J Clin Oncol, 13, 1221-30. |
28 | Tan BX, Yao WX, Ge J, et al (2011). Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer, 117, 5103-11. DOI ScienceOn |
29 | Tan HK, Moad AI, Tan ML (2014). The mTOR signalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals. Asian Pac J Cancer Prev, 15, 6463-75. DOI |
30 | Tang T, Lord JM, Norman RJ, et al (2012). Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiroinositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev, 5, 3053. |